查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080389

生物製藥市場：2026-2032年全球市場預測（依治療領域、技術、產品類型、給藥途徑及通路分類）

Biopharmaceuticals Market by Therapeutic Area, Technology, Product Type, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，生物製藥市場將成長至 8,703.1 億美元，複合年成長率為 6.66%。

主要市場統計數據
基準年 2025 5540.4億美元
預計年份：2026年 5891.2億美元
預測年份 2032 8703.1億美元
複合年成長率 (%) 6.66%

生物製藥執行摘要

生物製藥透過結合生物科學、先進製造技術和精準醫療，正在改變全球醫療保健，以應對腫瘤、免疫學、代謝紊亂、感染疾病和罕見疾病等高負擔疾病。此領域包括單株抗體、重組蛋白、疫苗、細胞和基因療法、RNA藥物、抗體藥物複合體（ADC）和生物相似藥。

生物製藥產業的變革性變化

生物製藥產業正從以數量為導向的藥物發現轉向利用平台進行精準開發。 mRNA、雙特異性抗體、抗體藥物複合體（ADC）、放射性藥物和體內基因編輯等療法正從專門的研發管線轉向主流的產品組合策略，這得益於疫情期間疫苗大規模生產的經驗教訓以及對監管機構更深入的了解。

人工智慧在生物製藥領域的累積影響

人工智慧正在對生物製藥研發、臨床開發、生產製造、藥物安全監測和商業化等各個領域產生累積影響。在藥物發現階段，人工智慧模型正在支援標靶辨識、蛋白質設計、小分子篩檢、生物標記選擇和轉化研究。由DeepMind和EMBL-EBI開發的AlphaFold蛋白質結構資料庫公開了超過2億個蛋白質的預測結構，顯著提高了結構生物學研究的可及性。

生物製藥市場的關鍵區域洞察

亞太地區是全球最具活力的生物製藥市場之一，這得益於中國的監管改革、日本成熟的創新生態系統、韓國的生物類似藥和合約研發生產（CDMO）能力、印度的疫苗和生技藥品製造地以及澳洲的臨床試驗基礎設施。該地區受益於大規模的患者群體、不斷擴大的醫保報銷體系、數位醫療的普及以及政府主導的生物技術投資，同時東南亞國協也在加強本地生產並協調監管。

戰略生物製藥板塊的關鍵群體分析

隨著東協各國政府致力於擴大全民健康覆蓋（UHC）、加強本地生技藥品生產能力、確保疫苗安全以及在監管問題上開展合作，東協市場的重要性日益凸顯。新加坡支持高附加價值研發和生產，而印尼、泰國、馬來西亞、越南和菲律賓對疫苗、癌症治療藥物、胰島素製劑、免疫療法和生物相似藥的需求不斷成長。

主要國家生物製藥產業的發展趨勢

美國憑藉FDA監管的研發流程、充裕的創業投資、對專科藥物的龐大需求、NIH支持的轉化科學以及連接大學與產業界的強大生態系統，引領全球生物製藥創新。加拿大則透過臨床研究、對生技藥品生產的投資、罕見疾病政策制定以及與國際標準高度一致的監管體系來支持市場發展。另一方面，墨西哥則充分利用其近岸外包、藥品生產、熟練的製造業勞動力以及接入北美供應鏈的優勢。巴西是拉丁美洲最大的醫療保健市場，受到ANVISA的監管，擁有公共免疫接種系統，並且對生物相似藥、疫苗和專科藥物的需求不斷成長。

為生物製藥行業領導者提供的實用建議

產業領導者應優先考慮治療平衡的產品組合，這些組合應結合短期生技藥品療效和差異化平台，例如抗體藥物複合體(ADC)、RNA 藥物、雙特異性抗體、放射性藥物以及細胞和基因療法。產品組合決策不僅應基於科學創新性，還應基於標靶有效性、臨床可行性、支付方價值、可生產擴充性、可擴展性、監管路徑清晰度和競爭格局等方面的證據。

調查方法

本執行摘要是根據已核實的二手資料的三角分析，包括來自 FDA、EMA、MHRA、PMDA、NMPA 和 WHO 的監管文件；ClinicalTrials.gov 等公開資料集；來自 OECD、WTO、世界銀行和國家衛生組織的政策文件；以及同行檢驗的檢驗期刊、公共文件、公共科學資料庫和認可的行業協會。

結論

生物製藥產業正步入一個以科學融合、加速數位化、區域化生產策略和基於價值的市場進入為特徵的新階段。儘管機會依然巨大，但競爭優勢越來越依賴系統性證據的累積、生產的可靠性、監管的靈活性、臨床差異化以及對支付方至關重要的結果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 生物製藥市場：依治療領域分類

  • 自體免疫
    • 發炎性腸道疾病
    • 銀屑病
    • 類風濕性關節炎
  • 心血管系統
    • 心臟衰竭
    • 高膽固醇症
    • 高血壓
  • 感染疾病
    • 抗生素
    • 抗病毒藥物
    • 疫苗
  • 神經病學
    • 阿茲海默症
    • 多發性硬化症
    • 帕金森氏症
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌
  • 罕見疾病
    • 囊腫纖維化
    • 血友病
    • 溶小體儲積症

第8章：生物製藥市場：依技術分類

  • 細胞培養
    • 哺乳動物
    • 微生物
  • 基因治療
    • 非病毒載體
    • 病毒載體
  • 融合瘤
  • 重組DNA

第9章 生物製藥市場：依產品類型分類

  • 生物相似藥
  • 學名藥

第10章：生物製藥市場：依給藥途徑分類

  • 吸入
  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下
  • 外用

第11章 生物製藥市場：依通路分類

  • 離線
  • 線上

第12章 生物製藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：生物製藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 生物製藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CSL Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Kyowa Kirin Co. Ltd.
  • Lonza Group AG
  • Merck & Co. Inc.
  • Moderna, Inc.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Samsung Biologics Co., Ltd.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • WuXi Biologics
Product Code: MRR-434CCDA05130

The Biopharmaceuticals Market is projected to grow by USD 870.31 billion at a CAGR of 6.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 554.04 billion
Estimated Year [2026] USD 589.12 billion
Forecast Year [2032] USD 870.31 billion
CAGR (%) 6.66%

Biopharmaceuticals Executive Summary

Biopharmaceuticals are reshaping global healthcare by combining biologic science, advanced manufacturing, and precision medicine to address high-burden diseases across oncology, immunology, metabolic disorders, infectious diseases, and rare conditions. The sector spans monoclonal antibodies, recombinant proteins, vaccines, cell and gene therapies, RNA-based medicines, antibody-drug conjugates, and biosimilars.

Demand is reinforced by aging populations, rising chronic disease prevalence, faster biomarker adoption, and health systems seeking durable clinical outcomes despite pricing and access pressures.

Transformative Shifts in the Biopharma Landscape

The biopharmaceutical landscape is shifting from volume-driven discovery toward precision, platform-enabled development. Modalities such as mRNA, bispecific antibodies, antibody-drug conjugates, radiopharmaceuticals, and in vivo gene editing are moving from specialized pipelines into mainstream portfolio strategy, supported by lessons from pandemic-era vaccine scale-up and improved regulatory familiarity.

Manufacturing is also transforming. Organizations are investing in single-use bioprocessing, continuous manufacturing, digital quality systems, regional fill-finish capacity, and cold-chain resilience to reduce supply disruption. At the same time, biosimilar uptake, drug pricing reform, and health technology assessment are forcing innovators to prove differentiated value through real-world evidence, companion diagnostics, pharmacoeconomic data, and measurable patient outcomes.

Cumulative Impact of Artificial Intelligence in Biopharma

Artificial intelligence is creating a cumulative impact across biopharmaceutical R&D, clinical development, manufacturing, pharmacovigilance, and commercialization. In discovery, AI models support target identification, protein design, small-molecule screening, biomarker selection, and translational research; the AlphaFold Protein Structure Database, developed by DeepMind and EMBL-EBI, has made predicted structures for more than 200 million proteins publicly available, materially improving access to structural biology.

In clinical operations, AI is being applied to protocol design, patient matching, site selection, medical imaging, document automation, and safety signal detection. The value is greatest when models are validated, explainable, and governed under GxP, privacy, cybersecurity, and regulatory expectations. Industry leaders are therefore moving from experimental AI pilots to controlled enterprise systems that combine curated data, human oversight, auditability, bias monitoring, and lifecycle model management.

Key Regional Insights Across Biopharmaceutical Markets

Asia-Pacific is one of the most dynamic biopharmaceutical arenas, supported by China's regulatory reforms, Japan's mature innovation ecosystem, South Korea's biosimilar and contract development and manufacturing capabilities, India's vaccine and biologics manufacturing base, and Australia's clinical trial infrastructure. The region benefits from large patient pools, expanding reimbursement mechanisms, digital health adoption, and government-backed biotechnology investment, while ASEAN economies are strengthening local production and regulatory alignment.

North America remains the leading innovation and commercialization hub, anchored by the United States' FDA framework, NIH-funded science, venture financing, specialty medicine adoption, and advanced biologics manufacturing, while Canada contributes clinical research networks, rare disease policy development, and biomanufacturing investments. Europe combines EMA centralized authorization, strong academic science, advanced therapy expertise, and extensive biosimilar experience, with Germany, France, Italy, Spain, and the United Kingdom shaping research, access, health technology assessment, and manufacturing priorities.

Latin America is advancing through Brazil's ANVISA-regulated biologics market, Mexico's pharmaceutical manufacturing base, and growing demand for specialty medicines, vaccines, and biosimilars, although reimbursement variability and budget constraints continue to affect uptake. The Middle East is prioritizing healthcare diversification, local manufacturing, and biotechnology investment, particularly across Saudi Arabia and the UAE. Africa remains underpenetrated but strategically important; the African Union's Partnerships for African Vaccine Manufacturing targets production of 60% of the continent's vaccine needs by 2040, signaling long-term regional biopharmaceutical capacity building.

Key Group Insights Across Strategic Biopharma Blocs

ASEAN markets are gaining importance as governments expand universal health coverage, local biologics capacity, vaccine security, and regulatory cooperation. Singapore supports high-value R&D and manufacturing, while Indonesia, Thailand, Malaysia, Vietnam, and the Philippines represent rising demand for vaccines, oncology therapies, insulin products, immunology treatments, and biosimilars.

The GCC is advancing biopharmaceutical localization through procurement reform, public-private partnerships, national industrial strategies, and investment in healthcare infrastructure. The European Union remains a reference market for centralized approvals, pharmacovigilance, biosimilar adoption, orphan drug regulation, and the EU Health Technology Assessment Regulation, which begins joint clinical assessments for selected medicines from 2025.

BRICS countries are central to supply chain diversification, clinical development, and domestic innovation, with China and India especially important for manufacturing scale, trial recruitment, and biosimilar development. G7 economies continue to lead in intellectual property systems, advanced R&D, regulatory science, premium launches, and medical innovation policy. NATO members increasingly view biopharmaceutical supply chains, vaccines, biologics manufacturing, and medical countermeasures as health security assets, reinforcing resilience planning and domestic capability investment.

Key Country Insights in Biopharmaceuticals

The United States leads global biopharmaceutical innovation through FDA-regulated development, deep venture capital, large specialty medicine demand, NIH-supported translational science, and a strong university-to-industry ecosystem. Canada supports the market through clinical research, biologics manufacturing investment, rare disease policy development, and strong regulatory alignment with international standards, while Mexico benefits from nearshoring, pharmaceutical production, skilled manufacturing labor, and access to North American supply chains. Brazil is Latin America's largest healthcare market, with ANVISA oversight, public immunization capacity, and expanding demand for biosimilars, vaccines, and specialty medicines.

In Europe, the United Kingdom remains influential in genomics, early clinical trials, health technology assessment, and the MHRA's post-Brexit regulatory pathway. Germany combines advanced manufacturing, strong reimbursement structures, and research-intensive biopharma capabilities. France emphasizes public research, health technology assessment, and industrial sovereignty; Italy and Spain are important for manufacturing, clinical trials, hospital-based specialty medicine use, and biosimilar adoption. Russia maintains domestic biologics capabilities but faces trade, regulatory, financing, and investment constraints that affect international integration.

China is scaling rapidly through NMPA reforms, domestic innovation, clinical trial expansion, and global licensing activity. India is a critical vaccine, biosimilar, and biologics manufacturing hub with cost-efficient development capacity and extensive process chemistry expertise. Japan offers premium reimbursement, PMDA regulatory maturity, aging-population demand, and leadership in regenerative medicine. Australia is attractive for early-phase trials, biomedical research quality, and R&D tax incentives, while South Korea is globally recognized for biosimilars, cell therapy investment, and large-scale contract biomanufacturing.

Actionable Recommendations for Biopharmaceutical Industry Leaders

Industry leaders should prioritize modality-balanced portfolios that combine near-term biologics performance with differentiated platforms such as antibody-drug conjugates, RNA medicines, bispecific antibodies, radiopharmaceuticals, and cell and gene therapies. Portfolio decisions should be grounded in target validation, clinical feasibility, payer value, manufacturability, scalability, regulatory pathway clarity, and competitive evidence rather than scientific novelty alone.

Organizations should strengthen AI governance, invest in interoperable data infrastructure, expand resilient manufacturing networks, and use real-world evidence earlier in development. Commercial teams must prepare for biosimilar competition, pricing reform, supply chain scrutiny, and stricter health technology assessment by building value dossiers that demonstrate survival benefit, quality-of-life gains, reduced hospital burden, adherence improvement, and durable outcomes.

Research Methodology

This executive summary is based on triangulation of verified secondary research, including regulatory publications from the FDA, EMA, MHRA, PMDA, NMPA, and WHO; public datasets such as ClinicalTrials.gov; policy sources from OECD, WTO, World Bank, and national health agencies; and peer-reviewed journals, public filings, public scientific databases, and recognized industry associations.

Insights were assessed using a structured market intelligence framework covering therapy modality, regulatory pathway, manufacturing capability, reimbursement environment, clinical trial activity, technology adoption, regional policy, supply chain resilience, and competitive positioning. Data points were cross-checked across multiple credible sources, and forward-looking interpretation was limited to observable policy, investment, regulatory, and technology adoption trends.

Conclusion

Biopharmaceuticals are entering a new phase defined by scientific convergence, digital acceleration, regional manufacturing strategies, and value-based market access. Opportunities remain substantial, but competitive advantage increasingly depends on disciplined evidence generation, manufacturing reliability, regulatory agility, clinical differentiation, and payer-relevant outcomes.

Organizations that combine high-quality science with AI-enabled operations, resilient supply chains, and region-specific access strategies will be best positioned to meet demand across mature and emerging markets. The next wave of leadership will belong to organizations that convert complex biology into scalable, affordable, and clinically meaningful therapies while maintaining quality, compliance, and patient trust.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biopharmaceuticals Market, by Therapeutic Area

  • 7.1. Autoimmune
    • 7.1.1. Inflammatory Bowel Disease
    • 7.1.2. Psoriasis
    • 7.1.3. Rheumatoid Arthritis
  • 7.2. Cardiovascular
    • 7.2.1. Heart Failure
    • 7.2.2. Hypercholesterolemia
    • 7.2.3. Hypertension
  • 7.3. Infectious Disease
    • 7.3.1. Antibiotics
    • 7.3.2. Antivirals
    • 7.3.3. Vaccines
  • 7.4. Neurology
    • 7.4.1. Alzheimers
    • 7.4.2. Multiple Sclerosis
    • 7.4.3. Parkinsons
  • 7.5. Oncology
    • 7.5.1. Hematological Malignancies
    • 7.5.2. Solid Tumors
  • 7.6. Rare Disease
    • 7.6.1. Cystic Fibrosis
    • 7.6.2. Hemophilia
    • 7.6.3. Lysosomal Storage Disorders

8. Biopharmaceuticals Market, by Technology

  • 8.1. Cell Culture
    • 8.1.1. Mammalian
    • 8.1.2. Microbial
  • 8.2. Gene Therapy
    • 8.2.1. Nonviral Vector
    • 8.2.2. Viral Vector
  • 8.3. Hybridoma
  • 8.4. Recombinant Dna

9. Biopharmaceuticals Market, by Product Type

  • 9.1. Biosimilars
  • 9.2. Generics

10. Biopharmaceuticals Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Oral
  • 10.5. Subcutaneous
  • 10.6. Topical

11. Biopharmaceuticals Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Biopharmaceuticals Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Biopharmaceuticals Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biopharmaceuticals Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Amgen Inc.
  • 16.3. AstraZeneca plc
  • 16.4. Bayer AG
  • 16.5. Biogen Inc.
  • 16.6. BioNTech SE
  • 16.7. Bristol-Myers Squibb Company
  • 16.8. CSL Limited
  • 16.9. Dr. Reddy's Laboratories Ltd.
  • 16.10. Eli Lilly and Company
  • 16.11. Gilead Sciences Inc.
  • 16.12. GlaxoSmithKline plc
  • 16.13. Incyte Corporation
  • 16.14. Intas Pharmaceuticals Ltd.
  • 16.15. Johnson & Johnson
  • 16.16. Kyowa Kirin Co. Ltd.
  • 16.17. Lonza Group AG
  • 16.18. Merck & Co. Inc.
  • 16.19. Moderna, Inc.
  • 16.20. Novartis International AG
  • 16.21. Novo Nordisk A/S
  • 16.22. Pfizer Inc.
  • 16.23. Regeneron Pharmaceuticals, Inc.
  • 16.24. Roche Holding AG
  • 16.25. Samsung Biologics Co., Ltd.
  • 16.26. Sanofi S.A.
  • 16.27. Takeda Pharmaceutical Company Limited
  • 16.28. WuXi Biologics

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICALS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOIMMUNE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYPERCHOLESTEROLEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HYPERCHOLESTEROLEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYPERCHOLESTEROLEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALZHEIMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALZHEIMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALZHEIMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PARKINSONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARKINSONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PARKINSONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RARE DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RARE DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RARE DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEMOPHILIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEMOPHILIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEMOPHILIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LYSOSOMAL STORAGE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LYSOSOMAL STORAGE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LYSOSOMAL STORAGE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MAMMALIAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MAMMALIAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MAMMALIAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MICROBIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MICROBIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MICROBIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NONVIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NONVIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NONVIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HYBRIDOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HYBRIDOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HYBRIDOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RECOMBINANT DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RECOMBINANT DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RECOMBINANT DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENERICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENERICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 232. GCC BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. GCC BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. G7 BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 274. G7 BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 275. G7 BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 276. G7 BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. G7 BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. G7 BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 282. G7 BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. G7 BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. G7 BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. NATO BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. NATO BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 289. NATO BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 290. NATO BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 291. NATO BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. NATO BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. NATO BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. NATO BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 296. NATO BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. NATO BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. NATO BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 323. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 325. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 334. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 337. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 338. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 339. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 340. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 342. MEXICO BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 343. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 345. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 346. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 347. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 348. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 349. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 350. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 351. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 352. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 353. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 354. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 356. BRAZIL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 361. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 362. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 363. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 364. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 365. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 366. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 367. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 368. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 369. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 370. UNITED KINGDOM BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 371. GERMANY BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILL